|
Multiple Sclerosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Subgroup analysis revealed that APOE ε4, 2 alleles were not associated with an increased risk of MS in Caucasian population (OR(c-ε4)=0.924, 95% CI=0.819-1.041; OR(c-ε2)=1.127, 95% CI=0.955-1.331).
|
21679970 |
2011 |
|
Multiple Sclerosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Apo E genotypes in multiple sclerosis, Parkinson's disease, schwannomas and late-onset Alzheimer's disease.
|
7700274 |
1994 |
|
Multiple Sclerosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Apolipoprotein E genotype does not influence the progression of multiple sclerosis.
|
14504972 |
2003 |
|
Multiple Sclerosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Inheritance of the apolipoprotein E (APOE) epsilon4 allele is associated with increased risk of Alzheimer disease, progression to disability in multiple sclerosis, and poor outcome after traumatic brain injury.
|
12810485 |
2003 |
|
Multiple Sclerosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
To investigate the association between apolipoprotein E (Apo E) genotype in multiple sclerosis (MS) and acute monosymptomatic optic neuritis (ON) in a genetically homogeneous population with a high frequency of the Apo epsilon4 allele.
|
16193886 |
2005 |
|
Multiple Sclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
The association between apolipoprotein E and multiple sclerosis.
|
16796581 |
2006 |
|
Multiple Sclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Despite pleiotropic immunomodulatory effects of apolipoprotein E (apoE) in vitro, its effects on the clinical course of experimental autoimmune encephalomyelitis (EAE) and multiple sclerosis (MS) are still controversial.
|
26669675 |
2015 |
|
Multiple Sclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
CONCLUSION - No association between cognitive impairment and ApoE-4 or clinical markers was detected in our MS patients.
|
21208197 |
2011 |
|
Multiple Sclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Apolipoprotein E and multiple sclerosis: a biochemical and genetic investigation.
|
9702689 |
1998 |
|
Multiple Sclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
While part of the association of the apoE polymorphism with AD is supposed to be caused by apoE-isoform dependent effects on amyloid-beta deposition, no single pathogenetically relevant mechanism has yet been confirmed for MS.
|
16631796 |
2006 |
|
Multiple Sclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
The presence of significant NBV decreases only in the group of RRMS patients with the ApoE epsilon4 genotype provides new evidence that links ApoE epsilon4-related impaired mechanisms of cell repair and severe tissue destruction in MS.
|
15096402 |
2004 |
|
Multiple Sclerosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Neuropsychological assessment, quantitative MRI and ApoE gene polymorphisms in a series of MS patients treated with IFN beta-1b.
|
16626758 |
2006 |
|
Multiple Sclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Apolipoprotein E ε4-positive multiple sclerosis patients develop more gray-matter and whole-brain atrophy: a 15-year disease history model based on a 4-year longitudinal study.
|
21324265 |
2010 |
|
Multiple Sclerosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The influence of APOE allelic heterogeneity on multiple sclerosis (MS) disease severity has been reported in multiple datasets with conflicting results.
|
19786693 |
2009 |
|
Multiple Sclerosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The authors studied the association of an exon 4 (E4*epsilon2/3/4) and three promoter polymorphisms of APOE with disease course and severity stratified by gender in 221 patients with multiple sclerosis from two overlapping population-based prevalence cohorts.
|
15007140 |
2004 |
|
Multiple Sclerosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Given the large sample size of our analyses, it is unlikely that the two APOE missense SNPs studied here exert any relevant effects on MS susceptibility.
|
22972946 |
2012 |
|
Multiple Sclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
We found an association of APOE epsilon4 with impaired verbal learning in patients with multiple sclerosis.
|
17310023 |
2007 |
|
Multiple Sclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
APOE epsilon4 and cognitive dysfunction in multiple sclerosis: a review.
|
20463109 |
2010 |
|
Multiple Sclerosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Influence of APOE gene polymorphisms on interferon-beta treatment response in multiple sclerosis.
|
21163235 |
2011 |
|
Multiple Sclerosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The purpose of the present study was to determine whether the ε4 allele of APOE is associated with more extensive brain pathology in MS using structural and diffusion tensor MRI.
|
21723395 |
2011 |
|
Multiple Sclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
However, the modest effects do not justify APOE genotyping of patients with MS in clinical practice.
|
17460153 |
2008 |
|
Multiple Sclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Recent clinical studies have identified an association between APOE 4 and cognitive deficits in patients with multiple sclerosis.
|
19422789 |
2009 |
|
Multiple Sclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Apolipoprotein E epsilon 4 is associated with rapid progression of multiple sclerosis.
|
11552016 |
2001 |
|
Multiple Sclerosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We performed (1)H-MRS of the central portion of both hemispheres and APOE genotyping in 72 patients (52 women and 20 men; mean +/- SD age, 34.8 +/- 8.8 years) with clinically definite relapsing-remitting MS.
|
12533090 |
2003 |
|
Multiple Sclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
An analysis of disease progression in 614 patients with MS from 379 families indicated that APOE-4 carriers are more likely to be affected with severe disease (P=.03), whereas a higher proportion of APOE-2 carriers exhibit a mild disease course (P=.02).
|
11836653 |
2002 |